Eridani Pharmaceuticals, Inc

Our lead asset, EP-837, is a novel oral TSHR agonist for patient friendly, cost-effective, diagnosis and treatment of differentiated thyroid cancer

  • Stage Product In Development
  • Industry Biotechnology
  • Location Doylestown, PA, US
  • Currency USD
  • Founded January 2016
  • Employees 5
  • Incorporation Type C-corp
  • Website http://lazaruspharma.com HOLDING COMPANY

Company Summary

Eridani Pharmaceuticals, Inc. is a Pennsylvania based pharmaceutical development company focused on developing an innovative, cost effective oral first-in-class therapy for the detection and treatment of thyroid cancer. The technology was licensed from the National Institutes of Health (NIH).

Eridani Pharmaceuticals, Inc. was formed as a joint venture by Lazarus Pharmaceuticals, LLC a pharmaceutical holding company and Nova Therapeutics, LLC.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free